Product Overview

Daonil 5 Mg is a prescription antidiabetic medication manufactured by Sanofi India Limited. Each strip contains 30 tablets, each delivering a precise 5 mg dose of glibenclamide, a well‑established sulfonylurea agent used in the management of type 2 diabetes mellitus. The product is packaged for convenience, offering pack sizes of 120, 180, and 300 tablets to suit long‑term therapy needs. Shipping typically occurs within six to fifteen days, ensuring a reliable supply for patients seeking consistent glycemic control. Daonil is indicated for patients whose blood glucose levels are not adequately controlled by diet and exercise alone, and it can be used as part of a comprehensive treatment plan that may include other glucose‑lowering agents. The tablets are film‑coated to protect the active ingredient and to ensure consistent absorption throughout the gastrointestinal tract. The medication is stored at room temperature, away from moisture and heat, to preserve its potency over the shelf life indicated on the packaging.

What is Daonil 5 Mg (Glibenclamide)

Daonil 5 Mg belongs to the sulfonylurea class of oral hypoglycemic drugs. The active moiety, glibenclamide, stimulates pancreatic beta‑cells to release insulin, thereby lowering fasting and post‑prandial glucose concentrations. This mechanism makes it a cornerstone therapy for adults with type 2 diabetes who have not achieved target HbA1c levels through lifestyle modification alone. The drug is marketed under the brand name Daonil in India and is produced by Sanofi India Limited, a subsidiary of the global Sanofi pharmaceutical group. Clinical guidelines from the National Institutes of Health (NIH) recognize sulfonylureas as effective first‑line oral agents when used appropriately.

For more detailed scientific background, you can review the NIH Diabetes Information page or consult the U.S. Food and Drug Administration (FDA) drug label database which provides regulatory insight into glibenclamide.

Uses and Benefits

Daonil 5 Mg is prescribed primarily to improve glycemic control in adults with type 2 diabetes mellitus. By enhancing insulin secretion, it helps reduce both fasting plasma glucose and overall post‑meal glucose excursions, which can lower the risk of long‑term complications such as cardiovascular disease, nephropathy, and retinopathy. Physicians often incorporate Daonil into a broader therapeutic regimen that may include metformin, dietary counseling, and physical activity. Real‑world studies cited by MedlinePlus demonstrate that consistent use of sulfonylureas can achieve a mean reduction of 0.5–1.0 % in HbA1c when combined with appropriate lifestyle changes. The tablet formulation offers convenient once‑daily dosing, supporting patient adherence and simplifying regimen management.

Patients often report improved energy levels and reduced symptoms of hyperglycemia, such as excessive thirst and frequent urination, after initiating therapy. The medication is also available in multiple pack sizes, allowing individuals to select a supply that matches their treatment duration and insurance coverage.

How It Works

Glibenclamide, the active ingredient in Daonil, binds to the sulfonylurea receptor (SUR1) on the surface of pancreatic beta‑cells. This interaction triggers the closure of ATP‑sensitive potassium channels, leading to cell depolarization and an influx of calcium ions. The resulting calcium surge promotes the exocytosis of insulin‑containing vesicles, causing a rapid increase in circulating insulin. Because insulin is the primary hormone that facilitates glucose uptake by muscle, fat, and liver cells, the net effect is a lowering of blood glucose concentrations. The pharmacodynamic profile of Daonil features a relatively short onset of action (approximately 1–2 hours) and a duration of effect lasting up to 24 hours, which supports once‑daily administration. For a deeper scientific explanation, refer to the Wikipedia entry on glibenclamide, which details the molecular interaction and clinical pharmacology.

Dosage Guidelines

The usual starting dose of Daonil is 5 mg taken once daily with breakfast, as food can enhance absorption and reduce gastrointestinal discomfort. Depending on the patient’s glycemic response, the physician may increase the dose in increments of 2.5–5 mg at intervals of 1–2 weeks, with a typical maximum daily dose of 15 mg. Dose adjustments are essential for elderly patients, those with renal or hepatic impairment, and individuals taking other medications that affect glucose metabolism. It is important to monitor blood glucose regularly and to adjust the dose only under professional supervision to avoid hypoglycemia. Patients should be instructed to take the tablet whole, without crushing or splitting, to preserve the controlled‑release characteristics of the formulation.

For additional guidance on dosing recommendations, the Drugs.com reference page provides a comprehensive overview of dosing strategies used in clinical practice.

Side Effects

Like all medications, Daonil can cause adverse effects, although not everyone experiences them. The most frequently reported side effects include hypoglycemia, gastrointestinal upset such as nausea or abdominal discomfort, and skin reactions like rash or itching. Less common but clinically significant events may involve liver enzyme elevations, weight gain, or rare hypersensitivity reactions requiring immediate medical attention. Prolonged hypoglycemia can lead to dizziness, confusion, or loss of consciousness, so patients should be aware of the signs and carry a source of glucose, such as glucose tablets or a sugary beverage, for emergency treatment. If any severe or persistent side effects occur, the medication should be discontinued and a healthcare professional consulted promptly.

For a detailed list of reported adverse events, consult the FDA drug label or the Mayo Clinic medication guide, which summarize safety data from clinical trials and post‑marketing surveillance.

Warnings and Precautions

Daonil is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe renal impairment (eGFR < 30 mL/min/1.73 m²). It should not be used during pregnancy or breastfeeding unless the benefits clearly outweigh the risks, and a clinician must provide individualized guidance. Caution is advised in patients with a history of cardiovascular disease, as rapid shifts in glucose can affect cardiac function. Alcohol consumption can potentiate the hypoglycemic effect, increasing the likelihood of dizziness or fainting. Patients scheduled for surgical procedures or diagnostic imaging involving contrast agents should inform their healthcare provider of Daonil use, as temporary discontinuation may be recommended to prevent hypoglycemia. Finally, regular laboratory monitoring of kidney function, liver enzymes, and electrolytes is recommended to ensure safe continued therapy.

Frequently Asked Questions

1. Q: Can Daonil be taken by patients with kidney disease?
   A: It should be used with caution; dose adjustment may be required, and regular kidney function tests are recommended. Consult your physician before starting therapy.
2. Q: What should I do if I miss a dose?
   A: Take the missed tablet as soon as you remember, unless it is near the time of the next scheduled dose. Do not double the dose to catch up.
3. Q: Is Daonil safe during pregnancy?
   A: Daonil is generally not recommended during pregnancy due to potential fetal risk; alternative therapies are preferred. Discuss with your healthcare provider for personalized advice.
4. Q: How long does it take to see improvements in blood sugar?
   A: Glycemic control may improve within a few days to weeks, but optimal HbA1c reduction typically occurs after 4–6 weeks of consistent use combined with diet and exercise.
5. Q: Can I drink alcohol while on Daonil?
   A: Alcohol can increase the risk of hypoglycemia; moderate consumption is advised, and you should monitor blood glucose closely.

Related Products

• Allegra (Fexofenadine)
• Fexofenadine 30 Mg (Generic)
• Fexofenadine 120 Mg (Generic)
• Fexofenadine 180 Mg (Generic)
• Allegra 120 mg (Fexofenadine)
• Allegra 30mg (Fexofenadine)
• Allegra Nasal Duo Spray (Fluticasone / Azelastine)
• Allegra 180 mg (Fexofenadine)
• Okamet 500 Mg (Metformin)
• Framycetin Sulphate Cream (Generic)
• Teicoplanin 400mg (Generic)
• Soframycin Cream (Framycetin Sulphate)